.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Myelodysplastic Syndromes: Translating Genetics to Clinical Practice

EP. 1: The Broad Spectrum of Myelodysplastic Syndrome

May 12th 2016

EP. 2: WHO Criteria and Diagnosis in MDS

May 12th 2016

EP. 3: Diagnostic Challenges: When Is It MDS

May 12th 2016

EP. 4: MDS Risk Stratification and Treatment

May 12th 2016

EP. 5: Comorbidities, Mutations, and Risk in MDS

May 12th 2016

EP. 6: Treatment Goals for Lower Risk MDS

May 12th 2016

EP. 7: Parameters for Blood Transfusion in MDS

May 12th 2016

EP. 8: Options in Low-Risk Myelodysplastic Syndrome

May 12th 2016

EP. 9: Management of Patients with MDS and Cytopenias

May 12th 2016

EP. 10: Treatment Goals for Higher Risk MDS

May 12th 2016

EP. 11: Hypomethylating Agents in MDS: Factors to Consider

May 12th 2016

EP. 12: Rationale for Combination Therapy in MDS

May 12th 2016

EP. 13: Emerging Approaches in MDS Treatment

May 12th 2016